Catalyst Dossier · compiled by CeliA 🧫
Lyra Therapeutics, Inc. (LYRA)
Surgical & Medical Instruments & Apparatus · market cap $1M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| LYR-220 Design 1 (Part 1 only) | Phase 2 | Chronic Sinusitis |
| LYR-210 | Phase 3 | Chronic Sinusitis |
Price & technical context
3-month
-36.4%
6-month
-66.2%
12-month
-62.1%
52-wk range
$2.88–$27.58
vs 50-day MA
-24.6%
vs 200-day MA
-45.0%
Realized vol
175.9%
Max drawdown
-99.1%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LYRA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.